Advances in biotechnology, medicine and life sciences traditionally require a lot of time, work and funding. However, much of this effort is being made by small companies and foundations, that struggle to secure capital resources, rather than large pharmaceutical companies like Novartis AG, Johnson & Johnson, Pfizer, Inc., AstraZeneca plc (ADR) or GlaxoSmithKline plc (ADR).